{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:33:05Z","timestamp":1666269185508},"reference-count":53,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:p>Desde o Diabetes Control and Complications Trial (DCCT), a terapia insul\u00ednica intensiva tem sido direcionada para alcan\u00e7ar valores de glicemia e hemoglobina glicada (HbA1c) t\u00e3o pr\u00f3ximos do normal quanto a seguran\u00e7a permita. Entretanto, a hiperglicemia (especialmente a hiperglicemia p\u00f3s-prandial) e a hipoglicemia continuam a ser um problema no manejo do diabetes tipo 1. O objetivo de associar outras drogas \u00e0 terapia insul\u00ednica \u00e9 diminuir a glicemia p\u00f3s-prandial. A terapia adjunta pode ser dividida em tr\u00eas grupos, conforme seu mecanismo de a\u00e7\u00e3o: 1. Aumento da a\u00e7\u00e3o da insulina (metformina e tiazolidinedionas); 2. Altera\u00e7\u00e3o da libera\u00e7\u00e3o de nutrientes no trato gastrintestinal (acarbose e amilina); 3. Outros modos de a\u00e7\u00e3o [pirenzepina, fator de crescimento insulina-s\u00edmile (IGF-1) e pept\u00eddeo semelhante ao glucagon 1 (GLP-1). Muitos desses agentes mostraram, em estudos de curto prazo, diminui\u00e7\u00e3o de 0,5% a 1% na HbA1c, diminuir a hiperglicemia p\u00f3s-prandial e as doses di\u00e1rias de insulina.<\/jats:p>","DOI":"10.1590\/s0004-27302008000200015","type":"journal-article","created":{"date-parts":[[2008,4,24]],"date-time":"2008-04-24T00:17:49Z","timestamp":1208996269000},"page":"279-287","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvantes no tratamento da hiperglicemia do diabetes melito tipo 1"],"prefix":"10.1590","volume":"52","author":[{"given":"M\u00f4nica de A. Lima","family":"Gabbay","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1590\/S0004-27302006000200011","article-title":"Resist\u00eancia \u00e0 insulina e s\u00edndrome metab\u00f3lica no diabetes melito do tipo 1","volume":"50","author":"Dib SA","year":"2006","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref3","first-page":"1036","article-title":"Insulin resistance in type 1 diabetes mellitus: a major role for reduced glucose extraction","volume":"81","author":"Makimattila S","year":"1996","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2337\/diabetes.52.10.2623","article-title":"Relation of family history of type 2 diabetes, hypoglycemia and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial","volume":"52","author":"Pumell JQ","year":"2003","journal-title":"Diabetes","ISSN":"http:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"issue":"3","key":"ref5","first-page":"S91","article-title":"S\u00edndrome Metab\u00f3lica atrav\u00e9s do espectro da resist\u00eancia \u00e0 insulina em adolescentes com toler\u00e2ncia normal a glicose","volume":"51","author":"Rocco ER","year":"2007","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms","volume":"58","author":"Wiernsperger NF","year":"1999","journal-title":"Drugs","ISSN":"http:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2337\/diacare.21.7.1167","article-title":"Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study","volume":"21","author":"Wei M","year":"1998","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(61)92002-5","article-title":"Dimethydiguanide in the treatment of diabetic children","volume":"I","author":"Ferguson AW","year":"1961","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1464-5491.2006.01966.x","article-title":"The effects of metformin on blood glucose control in overweight patients with Type 1 diabetes","volume":"23","author":"Khan ASA","year":"2006","journal-title":"Diabet Med","ISSN":"http:\/\/id.crossref.org\/issn\/0742-3071","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.2337\/diacare.25.12.2153","article-title":"The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients","volume":"25","author":"Meyer L","year":"2002","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1463-1326.2006.00599.x","article-title":"The adittion of Metformin in Type 1 Diabetes improves insulin sensitivity, diabetic control, body composition and patient well- being","volume":"9","author":"Moon R.J.","year":"2007","journal-title":"Diabet Obes Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2006-0241","article-title":"Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin","volume":"91","author":"Srinivasan S","year":"2006","journal-title":"J Clin Enocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/eje.0.1490323","article-title":"Metformin as an additional therapy in adolescents with poorly controlled type 1 diabetes: randomized placebo controlled trial with aspects on insulin sensitivity","volume":"149","author":"Sarnblad S","year":"2003","journal-title":"Eur J Endocrinol","ISSN":"http:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2337\/diacare.26.1.138","article-title":"Metformin as an adjunt therapy in adolescents with type 1 diabetes and insulin resistance","volume":"26","author":"Hamilton J","year":"2003","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diabetes.49.4.626","article-title":"Can clinical factors estimate insulin resistance in type 1 diabetes?","volume":"49","author":"Williams KV","year":"2000","journal-title":"Diabetes","ISSN":"http:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"issue":"3","key":"ref16","first-page":"S86","article-title":"Metformina melhora a sensibilidade \u00e0 insulina e o controle glic\u00eamico do diabetes melito tipo 1 com sobrepeso","volume":"51","author":"Gabbay MAL","year":"2007","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2337\/diacare.26.5.1655","article-title":"Metformin in type 1 diabetes: Is this a good or bad idea?","volume":"26","author":"Faichney JD","year":"2003","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.290.1.81","article-title":"Metformin and thiazolidinedione use in Medicare patients with heart failure","volume":"290","author":"Masoudi FA","year":"2003","journal-title":"JAMA","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.2337\/diacare.26.12.3356","article-title":"Safety issues on metformin use","volume":"26","author":"Aldasouqi SA","year":"2003","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki Jarvinen H","year":"2004","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/dmrr.262","article-title":"Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes","volume":"18","author":"Beales PE","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/dmrr.503","article-title":"Rosiglitazone combined with insulin preserves islet beta function in adult-onset latent autoimmune diabetes (LADA)","volume":"21","author":"Zhou Z","year":"2005","journal-title":"Diabetes Metab Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diacare.28.7.1562","article-title":"The effects of rosiglitazone on overweight subjects with type 1 diabetes","volume":"28","author":"Strowig S","year":"2005","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jpeds.2006.08.049","article-title":"Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes","volume":"149","author":"Zdravkovic V","year":"2006","journal-title":"J Pediatr","ISSN":"http:\/\/id.crossref.org\/issn\/0022-3476","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/pds.1470","article-title":"A compararison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes","volume":"16","author":"Gerrits CM","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2362.1994.tb02252.x","article-title":"Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes","volume":"24","author":"Goke B","year":"1994","journal-title":"Eur J Clin Invest","ISSN":"http:\/\/id.crossref.org\/issn\/0014-2972","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0168-8227(98)00070-9","article-title":"Effects of acarbose (Glucobay\u00ae) in person with type 1 diabetes: a multicentre study","volume":"41","author":"Sels JPJE","year":"1998","journal-title":"Diab Res Clin Prac"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1464-5491.1999.00047.x","article-title":"Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind , multicentre study","volume":"16","author":"Riccardi G","year":"1999","journal-title":"Diabet Med","ISSN":"http:\/\/id.crossref.org\/issn\/0742-3071","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.0742-3071.2001.00563.x","article-title":"Use of an a-glucosidase inhibitor to maintain glucose homoeostasis during post prandial exercise in intensively treated type 1 diabetes subjects","volume":"18","author":"Rabasa-Lhoret R","year":"2001","journal-title":"Diabet Med","ISSN":"http:\/\/id.crossref.org\/issn\/0742-3071","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer C","year":"2001","journal-title":"Curr Pharm Des"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"119s","DOI":"10.1177\/0145721706288S236","article-title":"Amylin replacement therapy in patients with type 1 diabetes","volume":"32","author":"Edelman SV","year":"2006","journal-title":"Diabetes Educator","ISSN":"http:\/\/id.crossref.org\/issn\/0145-7217","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1 year randomized controlled trial","volume":"21","author":"Ratner RE","year":"2004","journal-title":"Diabet Med","ISSN":"http:\/\/id.crossref.org\/issn\/0742-3071","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","article-title":"The Human Amylin Analog, Pramlintide, corrects postprandial Hyperglucagonemia in patients with type 1 diabetes","volume":"51","author":"Fineman MS","year":"2002","journal-title":"Metabolism","ISSN":"http:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2337\/diabetes.54.4.1100","article-title":"The role of Amylin and Glucagon in the Dampening of Glycemic excursions in children with Type 1 Diabetes","volume":"54","author":"Heptulla RA","year":"2005","journal-title":"Diabetes","ISSN":"http:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double blind placebo-controlled trial assessing Pramlintide treatment in the setting of Intensive Insulin Therapy in Type 1 Diabetes","volume":"29","author":"Edelman S","year":"2006","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1464-5491.2002.00657_1.x","article-title":"Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1","volume":"19","author":"Ahr\u00e9n B","year":"2002","journal-title":"Diabet Med","ISSN":"http:\/\/id.crossref.org\/issn\/0742-3071","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-2265.2002.01656.x","article-title":"Insulin sensitivity and lipolysis in adolescent girls with poorly controlled type 1 diabetes: effect of anticholinergic treatment","volume":"57","author":"Halldin UM","year":"2002","journal-title":"Clin Endocrinol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1651-2227.1996.tb13886.x","article-title":"Reduced growth hormone secretion improves insulin sensitivity in adolescent girls with type 1 diabetes","volume":"85","author":"\u00c2man J","year":"1996","journal-title":"Acta Paediatr","ISSN":"http:\/\/id.crossref.org\/issn\/0001-656X","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/diabetes.49.5.789","article-title":"IGF-1 Treatment in adults with type 1 diabetes: efftects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic -euglycemic amino acid clamp","volume":"49","author":"Carroll PV","year":"2000","journal-title":"Diabetes","ISSN":"http:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2337\/diacare.22.4.585","article-title":"Cotherapy with recombinant human insulin-like growth factor i and insulin improves glycemic control in type 1 diabetes","volume":"22","author":"Thrailkill KM","year":"1999","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI30076","article-title":"The role of gut hormones in glucose homeostasis","volume":"117","author":"Drucker DJ","year":"2007","journal-title":"J Clin Invest","ISSN":"http:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1210\/en.2004-0015","article-title":"Minireview: Glucagon-Like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system","volume":"145","author":"Brubaker PL","year":"2004","journal-title":"Endocrinology","ISSN":"http:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.diabres.2006.03.022","article-title":"Effect of glucagon-like peptide -1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes","volume":"74","author":"Fung M","year":"2006","journal-title":"Diab Res Clin Pract"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.regpep.2004.06.003","article-title":"Glycaemic effects of incretins in type 1 diabetes mellitus: A concise review, with enphasis on studies in humans","volume":"128","author":"Dupre J","year":"2005","journal-title":"Regul Pept","ISSN":"http:\/\/id.crossref.org\/issn\/0167-0115","issn-type":"print"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/diabetes.51.4.951","article-title":"Impaired b-Cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose","volume":"51","author":"Greenbaum CJ","year":"2002","journal-title":"Diabetes","ISSN":"http:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2337\/diacare.13.7.806","article-title":"Immuno-supression in IDDM: rationale, risks, benefits and strategies","volume":"13","author":"Mahon JL","year":"1996","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diacare.19.6.580","article-title":"Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) aide in type 1 diabetic patients","volume":"19","author":"Creutzfeldt WO","year":"1996","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide -1 (7-36) amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak M","year":"1992","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diab.44.6.626","article-title":"Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM","volume":"44","author":"Dupre J","year":"1995","journal-title":"Diabetes","ISSN":"http:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"issue":"3","key":"ref51","article-title":"Glucagon-like peptide 1 improved glycemic control in type 1 diabetes","volume":"3","author":"Behme MT","year":"2003","journal-title":"BMC Endocr Disord"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1210\/jc.2003-032001","article-title":"Exendin-4 normalized post cibal glycemic excursions in type 1 diabetes","author":"Dupre J","year":"2004","journal-title":"J Clin Endocrinol Metab","ISSN":"http:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1399-543X.2006.00159.x","article-title":"Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations","volume":"7","author":"Jeha GS","year":"2006","journal-title":"Pediat Diab"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v52n2\/15.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T20:42:56Z","timestamp":1495744976000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302008000200015&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0004-27302008000200015"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302008000200015","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}